Basic Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 16, 2018; 6(8): 183-191
Published online Aug 16, 2018. doi: 10.12998/wjcc.v6.i8.183
Antiviral effects of hepatitis B virus S gene-specific anti-gene locked nucleic acid in transgenic mice
Shu-Rong Xiao, Gui-Dan Xu, Wu-Jun Wei, Bin Peng, Yi-Bin Deng
Shu-Rong Xiao, Gui-Dan Xu, Wu-Jun Wei, Bin Peng, Yi-Bin Deng, Department of Medical Laboratory Science, the Affiliated Hospital of Youjiang Medical College for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China
Yi-Bin Deng, Department of Hepatobiliary Disease Center, Guangxi Clinic Medicine Research, Baise 533000, Guangxi Zhuang Autonomous Region, China
Author contributions: Xiao SR and Deng YB conceived the study, analyzed the data, drafted the manuscript; Xu GD and Wei WJ helped revise the manuscript critically for important intellectual content; Peng B collect the data; Deng YB helped design the study.
Supported by National Natural Science Foundation of China, No. 81460123; Guangxi Graduate Innovation Program, No. 201601005; and Guangxi Clinic Medicine Research Center of Hepatobiliary Disease, No. AD17129025.
Institutional review board statement: This study was approved by the Affiliated Hospital of Youjiang Medical College for Nationalities, Baise, China.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Animal Ethics and Welfare Committee of Affiliated Hospital of Youjiang Medical College for Nationalities.
Conflict-of-interest statement: The authors declare that they have no competing interests.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yi-Bin Deng, PhD, Professor, Department of Medical Laboratory Science, the Affiliated Hospital of Youjiang Medical College for Nationalities, 18 Zhongshan 2nd Road, Baise 533000, Guangxi Zhuang Autonomous Region, China. enbin0776@sina.com
Telephone: +86-776-2852592 Fax: +86-776-2852592
Received: January 24, 2018
Peer-review started: February 2, 2018
First decision: March 7, 2018
Revised: March 29, 2018
Accepted: June 7, 2018
Article in press: June 8, 2018
Published online: August 16, 2018
ARTICLE HIGHLIGHTS
Research background

Hepatitis B virus (HBV) is one of the most severe human pathogens. It is reported that 240 million individuals globally are chronically infected with HBV and current antivirals cannot clear the infection or adequately suppress disease.

Research motivation

Despite improvement in global access to vaccination and treatment, mortality levels remain high. Chronic hepatitis B can be effectively and safely treated but a cure remains elusive.

Research objectives

The aim of this study is to inhibit HBV DNA expression with anti-gene locked nucleic acid (LNA) in transgenic mice.

Research methods

The aim of this study was to design liposome based transport of a LNA modified oligonucleotide to inhibit HBV DNA express in transgenic mice, the final objective was to assess the antiviral effects of HBV S gene-specific anti-gene LNA in transgenic mice.

Research results

Average rate reductions of HBsAg, HBV DNA, mRNA levels of the HBV S gene and the rate of HBsAg positive liver cells, with statistically significant differences compared with pre-treatment and control values (P < 0.05 for all). Liver and kidney function, and histology showed no abnormalities.

Research conclusions

Anti-gene-LNA transacted by cationic liposomes can effectively enter nucleolus in the liver of transgenic mice after tail vein injection and play a role in reducing HBV DNA replication and transcription.

Research perspectives

Based on the data presented herein highlight the usefulness of anti-gene-LNA mediated silencing HBV DNA replication and transcription bring forth innovative ideas and potentially viable tool for gene therapy.